Oncolytic viruses in Lymphoma V1.0
Research type
Research Study
Full title
Studies of the use of oncolytic viruses and other immunomodulatory compounds in Lymphoma.
IRAS ID
239098
Contact name
Andrew Chan
Contact email
Sponsor organisation
Sheffield Teaching Hospitals NHS Foundation Trust
Clinicaltrials.gov Identifier
not applicable, not applicable
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Lymphoma is a cancer of the lymphocytes (white blood cells) it comprises 5% of cancer cases in the UK and although survival rates have improved, patients with relapsed or refractory disease still have limited treatment options. In order to find novel treatments for Lymphoma laboratory models are needed. To make these models we will ask patients to donate blood, bone marrow, cerebrospinal fluid or lymph node collected at the time of clinical sampling.
We will then use these models to test new treaments such as oncolytic (cancer killing) viruses alone and in combination with existing treatments. Oncolytic viruses are an emerging treatment option for many malignancies and the first oncolytic virus has been approved for the treatment of melanoma by the FDA.
The long term aim is to improve treatment and therefore survival of patients with Lymphoma.
REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
18/YH/0318
Date of REC Opinion
9 Oct 2018
REC opinion
Further Information Favourable Opinion